Read Time:26 Second
Orchard Therapeutics shares ORTX nearly doubled, to $15.79, after agreeing to be purchased by Japan’s Kyowa Kirin JP:4151 for at least $16 per share in cash, plus an additional contingent value right of $1 per share. The total consideration will be as much as $478 million. London-based Orchard Therapeutics uses a patient’s own stem cells to produce therapies.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
